Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$6.09
-0.22 (-3.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-12.4M · quality 57.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$168M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-35.9%
↓Gross Margin
66.2%
↑Debt/Equity
0.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+6.8%
FCF CAGR
—
FCF margin
-20.1%
FCF / Net income
1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $61.9M · net income $-11.4M · FCF $-12.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $61.9M | $61.9M | $56.1M | $79.2M | $73.7M | $63.1M | $44.5M |
| Net Income | $-11.4M | $-11.4M | $-14.7M | $-3.9M | $-29.6M | $-44.0M | $5.3M |
| EBITDA | $-3.3M | $-3.3M | $-8.4M | $1.9M | $-23.2M | $-34.9M | $7.9M |
| EPS | — | — | -0.72 | -0.21 | -1.69 | -4.32 | 0.49 |
| Gross Margin | 66.2% | 66.2% | 62.8% | 71.1% | 58.2% | — | — |
| Operating Margin | -13.2% | -13.2% | -32.5% | 1.4% | -37.4% | -55.2% | 17.6% |
| Net Margin | -18.5% | -18.5% | -26.1% | -4.9% | -40.2% | -69.7% | 11.9% |
| Balance Sheet | |||||||
| Debt/Equity | 0.80 | 0.80 | 1.25 | 0.72 | 1.35 | — | — |
| Current Ratio | 1.72 | 1.72 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-12.4M | $-12.4M | $-24.1M | $240000.00 | $-33.5M | — | — |
| Returns | |||||||
| ROE | -35.9% | -35.9% | -73.1% | -18.9% | -174.5% | -104.6% | 51.3% |
| Valuation | |||||||
| EV/EBITDA | — | — | — | 41.31 | — | — | — |
| P/B | 5.19 | 5.19 | 4.34 | 4.52 | 1.69 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 10.2% | 10.2% | -29.1% | 7.5% | — | 41.8% | — |
| EPS Growth | — | — | -242.9% | 87.6% | — | -981.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.72 → n/d
Residual
-24.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.